Protagonist Therapeutics (PTGX) Competitors $40.69 -0.77 (-1.86%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PTGX vs. ITCI, ROIV, ASND, RVMD, LNTH, NUVL, BPMC, ELAN, LEGN, and CYTKShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Blueprint Medicines Elanco Animal Health Legend Biotech Cytokinetics Intra-Cellular Therapies (NASDAQ:ITCI) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Do insiders and institutionals hold more shares of ITCI or PTGX? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer ITCI or PTGX? Intra-Cellular Therapies currently has a consensus target price of $97.23, indicating a potential upside of 11.81%. Protagonist Therapeutics has a consensus target price of $53.78, indicating a potential upside of 32.16%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ITCI or PTGX? Intra-Cellular Therapies received 243 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 67.84% of users gave Intra-Cellular Therapies an outperform vote while only 60.83% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% Protagonist TherapeuticsOutperform Votes27860.83% Underperform Votes17939.17% Which has more risk & volatility, ITCI or PTGX? Intra-Cellular Therapies has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Is ITCI or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Intra-Cellular Therapies' net margin of -14.07%. Protagonist Therapeutics' return on equity of 34.68% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Protagonist Therapeutics 52.76%34.68%30.98% Does the media refer more to ITCI or PTGX? In the previous week, Intra-Cellular Therapies had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 7 mentions for Intra-Cellular Therapies and 5 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.10 beat Intra-Cellular Therapies' score of 0.65 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, ITCI or PTGX? Protagonist Therapeutics has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$612.78M15.04-$139.67M-$0.87-99.95Protagonist Therapeutics$323.80M7.49-$78.96M$2.6615.30 SummaryProtagonist Therapeutics beats Intra-Cellular Therapies on 13 of the 19 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.43B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio15.3010.75135.1817.53Price / Sales7.49287.861,235.42140.39Price / CashN/A56.6540.6537.95Price / Book6.975.394.884.92Net Income-$78.96M$152.04M$118.97M$225.78M7 Day Performance-0.76%-4.32%16.19%-1.58%1 Month Performance0.74%2.80%16.02%6.67%1 Year Performance96.29%17.30%34.95%22.48% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics3.653 of 5 stars$40.69-1.9%$53.78+32.2%+93.1%$2.43B$323.80M15.30125Positive NewsITCIIntra-Cellular Therapies4.1678 of 5 stars$84.74+2.1%$97.23+14.7%+32.9%$8.98B$612.78M-95.91560ROIVRoivant Sciences2.667 of 5 stars$12.05+1.8%$17.93+48.8%+8.9%$8.77B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$135.89+4.6%$191.77+41.1%+16.0%$8.24B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.80-0.5%$63.67+42.1%+69.6%$7.54B$11.58M-12.54443Positive NewsLNTHLantheus4.4014 of 5 stars$94.48+1.6%$130.00+37.6%+21.9%$6.57B$1.50B15.42834Positive NewsNUVLNuvalent2.3475 of 5 stars$86.95+0.1%$112.60+29.5%+9.7%$6.18BN/A-25.0340Positive NewsBPMCBlueprint Medicines2.9172 of 5 stars$95.20+2.2%$122.11+28.3%+9.7%$6.05B$434.42M-45.28640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.18+0.7%$16.75+37.5%-10.5%$6.02B$4.45B30.259,300LEGNLegend Biotech1.6722 of 5 stars$32.76-6.7%$81.54+148.9%-43.4%$5.98B$520.18M-36.971,800CYTKCytokinetics3.9849 of 5 stars$49.08+0.9%$83.93+71.0%+32.5%$5.79B$3.22M-9.04250 Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Lantheus Alternatives Nuvalent Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTGX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
